兆科眼科的合作夥伴Vyluma發表用於治療兒童近視加深的NVK002之第III期CHAMP臨床試驗的正面研究結果
Retrieved on:
Friday, October 28, 2022
Analysis of this multi-center, international study, performed after three years of treatment and follow up, demonstrates strong safety and efficacy for NVK002 as a potential treatment for the progression of myopia in children.
Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, said, "Innovation and commercialization are Zhaoke Ophthalmology's dual focuses for 2022.